The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Differential Diagnosis of Alzheimer Disease With Cerebrospinal Fluid Levels of Tau Protein Phosphorylated at Threonine 231
Abstract
BACKGROUND: Phosphorylation of tau protein at threonine 231 (using full-length tau, 441 amino acids, for the numbering scheme) (p-tau(231)) occurs specifically in postmortem brain tissue of patients with Alzheimer disease (AD) and can be sensitively detected in cerebrospinal fluid (CSF). OBJECTIVES: To determine to what extent CSF levels of p-tau(231) distinguish patients with AD from control subjects and from patients with other dementias, and to investigate whether p-tau(231) levels are a better diagnostic marker than levels of total tau protein (t-tau) in CSF. DESIGN AND SETTING: Cross-sectional, multicenter, memory clinic-based studies. PARTICIPANTS: One hundred ninety-two patients with a clinical diagnosis of AD, frontotemporal dementia (FTD), vascular dementia, Lewy body dementia, or other neurological disorder and healthy controls. MAIN OUTCOME MEASURES: Levels of CSF tau proteins as measured with enzyme-linked immunosorbent assays. RESULTS: Mean CSF levels of p-tau(231) were significantly elevated in the AD group compared with all other groups. Levels of p-tau(231) did not correlate with dementia severity in AD, and discriminated with a sensitivity of 90.2% and a specificity of 80.0% between AD and all non-AD disorders. Moreover, p-tau(231) levels improved diagnostic accuracy compared with t-tau levels when patients with AD were compared with healthy controls (P =.03) and demented subjects (P<.001), particularly those with FTD (P<.001), but not those with vascular and Lewy body dementias. Sensitivity levels between AD and FTD were raised by p-tau(231) compared with t-tau levels from 57.7% to 90.2% at a specificity level of 92.3% for both markers. CONCLUSION: Increased levels of CSF p-tau(231) may be a useful, clinically applicable biological marker for the differential diagnosis of AD, particularly for distinguishing AD from FTD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Hanley, J. A., & McNeil, B. J. (1983) · Radiology · doi:10.1148/radiology.148.3.6878708 · Cited by 7,016
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
Moms, J. C., Heyman, A., Mohs, R. C., Hughes, J. P., van Belle, G., Fillenbaum, G., Mellits, E. D., & Clark, C. (1989) · Neurology · doi:10.1212/wnl.39.9.1159 · Cited by 4,130
McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960
Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF
Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C., Riemenschneider, M., Deyn, P. P. D., Bancher, C., Cras, P., Wiltfang, J., Mehta, P. D., et al. (1999) · Neurology · doi:10.1212/wnl.52.8.1555 · Cited by 724
Self-citationConsensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”
(1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00022-0 · Cited by 666
Vanmechelen, E., Vanderstichele, H., Davidsson, P., Van Kerschaver, E., Van Der Perre, B., Sjögren, M., Andreasen, N., & Blennow, K. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01036-3 · Cited by 488
Self-citationElevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease
Otto, M., Wiltfang, J., Tumani, H., Zerr, I., Lantsch, M., Kornhuber, J., Weber, T., Kretzschmar, H. A., & Poser, S. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00215-2 · Cited by 341
Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease
Arai, H., Terajima, M., Miura, M., Higuchi, S., Muramatsu, T., Machida, N., Seiki, H., Takase, S., Clark, C. M., Lee, V. M. ‐., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380414 · Cited by 298
Self-citationCSF Total tau, Aβ42 and Phosphorylated tau Protein as Biomarkers for Alzheimer's Disease
Blennow, K., Vanmechelen, E., & Hampel, H. (2001) · Molecular Neurobiology · doi:10.1385/mn:24:1-3:087 · Cited by 267
Self-citationItoh, N., Arai, H., Urakami, K., Ishiguro, K., Ohno, H., Hampel, H., Buerger, K., Wiltfang, J., Otto, M., Kretzschmar, H., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1054 · Cited by 256 · cited 1×
“Our findings on the high discriminative power of CSF p-tau231 level as a single biomarker between the AD and non-AD groups are consistent with those of a report on CSF tau phosphorylated at serine 199.(12) In addition, we show the potential of p-tau231 to discriminate patients with AD from those with other relevant de…”
ResultSelf-citationBoth total and phosphorylated tau are increased in Alzheimer's disease
Sjogren, M. (2001) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.70.5.624 · Cited by 253
Andreasen, N., Vanmechelen, E., Van de Voorde, A., Davidsson, P., Hesse, C., Tarvonen, S., Raiha, I., Sourander, L., Winblad, B., & Blennow, K. (1998) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.64.3.298 · Cited by 227
Self-citationGlucose Hypometabolism and Neuropathological Correlates in Brains of Dementia with Lewy Bodies
Higuchi, M., Tashiro, M., Arai, H., Okamura, N., Hara, S., Higuchi, S., Itoh, M., Shin, R.-W., Trojanowski, J. Q., & Sasaki, H. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7342 · Cited by 206
Self-citationMitotic phosphoepitopes precede paired helical filaments in Alzheimer’s disease
Vincent, I., Zheng, J.-H., Dickson, D. W., Kress, Y., & Davies, P. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00071-2 · Cited by 176
Self-citationKohnken, R., Buerger, K., Zinkowski, R., Miller, C., Kerkman, D., DeBernardis, J., Shen, J., Möller, H.-J., Davies, P., & Hampel, H. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01178-2 · Cited by 173
Self-citationGreen, A. J. E., Harvey, R. J., Thompson, E. J., & Rossor, M. N. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00904-5 · Cited by 166
Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease
Galasko, D. R., Clark, C., Chang, L., Miller, B. L., Green, R. C., Motter, R. N., & Seubert, P. A. (1997) · Neurology · doi:10.1212/wnl.48.3.632 · Cited by 166
Parnetti, L., Lanari, A., Amici, S., Gallai, V., Vanmechelen, E., & Hulstaert, F. (2001) · Neurological Sciences · doi:10.1007/s100720170055 · Cited by 141 · cited 1×
“Levels of CSF tau phosphorylated at threonine 181 were elevated in patients with AD compared with those with other dementias and healthy control subjects.(13,14) Itoh and colleagues(12) showed that CSF tau phosphorylated at serine 199 disORIGINAL CONTRIBUTION”
ResultClinical-neuropathologic findings in multi-infarct dementia: A report of six autopsied cases
Hulette, C., Nochlin, D., McKeel, D., Morris, J. C., Mirra, S. S., Sumi, S. M., & Heyman, A. (1997) · Neurology · doi:10.1212/wnl.48.3.668 · Cited by 138
Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies
Gómez‐Isla, T., Growdon, W., McNamara, M. J., Newell, K. L., Gómez‐Tortosa, E., Hedley‐Whyte, E. T., & Hyman, B. T. (1999) · Neurology · doi:10.1212/wnl.53.9.2003 · Cited by 126
Hampel, H. J., Büerger, K., Kohnken, R. E., Teipel, S. J., Zinkowski, R. P., Moeller, H., Rapoport, S. I., & Davies, P. (2001) · Annals of Neurology · doi:10.1002/ana.111 · Cited by 102
Self-citationCombined assessment of tau and neuronal thread protein in Alzheimer’s disease CSF
Averback, P. (2000) · Neurology · doi:10.1212/wnl.55.7.1068 · Cited by 89
Tau protein is a potential biological marker for normal pressure hydrocephalus
Kudo, T., Mima, T., Hashimoto, R., Nakao, K., Morihara, T., Tanimukai, H., Tsujio, I., Koike, Y., Tagami, S., Mori, H., et al. (2000) · Psychiatry and Clinical Neurosciences · doi:10.1046/j.1440-1819.2000.00658.x · Cited by 80
Delacourte, A. (1999) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051218 · Cited by 39
Cited by
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Gauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K., Belleville, S., Brodaty, H., Bennett, D., Chertkow, H., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 3,850
Self-citationCSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Self-citationMcKeith, I., Mintzer, J., Aarsland, D., Burn, D., Chiu, H., Cohen-Mansfield, J., Dickson, D., Dubois, B., Duda, J. E., Feldman, H., et al. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00619-7 · Cited by 618
Brain Glucose Hypometabolism and Oxidative Stress in Preclinical Alzheimer's Disease
Mosconi, L., Pupi, A., & De Leon, M. J. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.007 · Cited by 595
Metadata
- Authors
- Buerger, K., Zinkowski, R., Teipel, S. J., Tapiola, T., Arai, H., Blennow, K., Andreasen, N., Hofmann-Kiefer, K., DeBernardis, J., Kerkman, D., McCulloch, C., Kohnken, R., Padberg, F., Pirttilä, T., Schapiro, M. B., Rapoport, S. I., Möller, H.-J., Davies, P., & Hampel, H.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2002-08-01
- Volume
- 59
- Issue
- 8
- Pages
- 1267
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W1971647405
- Cited by
- 277
- References
- 26
- FWCI
- 10.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.